16th June 2021
Six Scandinavian start-ups ready for EIT Health Catapult Semifinals
42 startups from across Europe with 6 based in Scandinavia have been selected for the EIT Health Catapult semi-finals with an €210 000 investment prize fund and the Audience Award Winner displayed on the New York Nasdaq Tower.
The 6 start-ups were selected through remote evaluation followed by a pitch competition in May with 4 companies based in Finland, and 2 based in Sweden. The selected start-ups develop innovative products and services within digital health, biotech and medtech. The start-ups will receive intensive training from experts, meet investors and businesses during October and November, and compete in pitch competitions for a chance to enter the finals at the next EIT Health Summit in 2022.
-Through the EIT Health Catapult program we help innovative start-ups from all over Europe to build and strengthen their value proposition and business plan, prepare for investments in the European life science landscape and provide them with great network opportunities with investors and innovators from within and outside the EIT Health network, says Christos Vaitsis, Business Creation Manager at EIT Health Scandinavia.
EIT Health Scandinavia have supported numerous companies through the Catapult programme since its start six years ago. Finnish Popit who participated in the Catapult programme last year, has recently partnered with Ashfield Engage to improve patient adherence in oral solid dosage (OSD) treatments and advance supplemental personalised patient support. Another Catapult company from last year, Swedish Ondosis, develop intelligent solutions to deliver individualised medication, completed a private placement of SEK 92 million led by Aeternum Capital.
-These start-ups have very innovative solutions, the fact that we are able to support them and help them accelerate their business and come closer to investments and partnering is very rewarding. In the long term, we believe that they will be able to significantly improve the lives of patients and citizens.” says, Erik Forsberg, Managing Director, EIT Health Scandinavia.
The Selected start-ups are:
Finnadvance (Finland) is growing human diseases in miniature chips for accelerating drug discovery and ultimately lead to better personalized medicines.
Prateek Singh email@example.com
APLEX Bio (Sweden) develops and offers reagents that enable highly parallelised detection of biomarkers in-situ in a disruptively easy and cost-efficient way.
Umear Naseem firstname.lastname@example.org
LS CancerDiag (Finland) wants to save millions of lives by preventing cancer and enable personalised care through an early detection of Lynch syndrome.
Niklas Lahti email@example.com
Medvasc (Sweden) is aiming to optimise the anaesthesia procedure in laser treatment of varicose veins and by that solve a vast unmet medical need.
Ingela Hallberg firstname.lastname@example.org
KAMU Health (Finland) develops and markets digital therapeutics for respiratory-illness care.
Seppo Salorinne email@example.com
Cardiolyse (Finland) provides cloud-based heart health analytics, that enables remote vital sign monitoring and personalised patient reports to provide better care.
Normunds Daudiss firstname.lastname@example.org
The EIT Health Catapult is inviting investors and experts to attend the virtual Semi-finals, from 1-3 December 2021, for the pitches and for matchmaking. These events provide the opportunity to make early contacts with the healthcare leaders of tomorrow. Find out more and register.
Dates for the public pitch days of the semi-finals are:
Biotech: 1 December 2021
Medtech: 2 December 2021
Digital Health: 3 December 2021